Opinion

Video

Antibodies to Screen for Type 1 Diabetes

Author(s):

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE

Dr Fran Cogen discusses the screening of autoantibodies for type 1 diabetes and provides insights on how to interpret the results of the screening tests.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Related Content
FDA logo in black over a white background. | Credit: US Food and Drug Administration
December 20th 2024

FDA Issues CRL for Sotagliflozin in Type 1 Diabetes and CKD

Patrick Campbell
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Aldosterone Dysregulation Linked to Notable Risk of Hypertension | Image Credit: CMHC
December 14th 2024

Aldosterone Dysregulation Linked to Notable Risk of Hypertension

Connor Iapoce
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Mifepristone Significantly Reduces HbA1c in Treatment Phase of CATALYST | Image Credit: LinkedIn
December 12th 2024

Mifepristone Notably Reduces HbA1c in Treatment Phase of CATALYST Trial

Connor Iapoce
A Pillared Approach: A Suite of THerapies for a Spectrum of Metabolic Disease
December 6th 2024

A Pillared Approach: A Suite of Therapies for a Spectrum of Metabolic Disease

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.